IVERIC bio Inc. (NASDAQ:ISEE) finished Wednesday with an addition of $0.18 to close at $21.03, an upside of 0.86 percent. An average of 1,480,120 shares of common stock have been traded in the last five days. There was a fall of -$1.54 in the past week, and it reached a new high 18 times over the past 12 months. The last 20 days have seen an average of 2,562,260 shares traded, while the 50-day average volume stands at 2,814,412.
ISEE stock has decreased by -5.70% in the last month. The company shares reached their 1-month lowest point of $20.05 on 12/12/22. With the stock rallying to its 52-week high on 10/31/22, shares of the company touched a low of $8.85 and a high of $24.33 in 52 weeks. It has reached a new high 16 times so far this year and achieved 25.78% or $4.31 in price. In spite of this, the price is down -13.56% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ISEE stock investors should be aware that IVERIC bio Inc. (ISEE) stock had its last reported insider trading activity 10 days ago on Dec 19. In this transaction, the insider spent $144,977. CFO, Carroll David Francis, disposed of 5,671 shares at a price of $21.51 on Dec 19. The insider now owns more than $121,983 worth of shares. Prior to that, CEO SBLENDORIO GLENN went on to Sale 19,457 shares at $21.51 each on Dec 19. An amount of $418,520 was transacted.
IVERIC bio Inc. (ISEE) stock’s beta is 1.04. Other valuation ratios to consider include the price-to-book (PB) ratio at 9.74.
The quick ratio of IVERIC bio Inc. for the three months ended June 29 was 13.40, and the current ratio was 13.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $114.76 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, IVERIC bio Inc.’s return on assets was -45.70%.
For the three-month period that ended June 29, IVERIC bio Inc. had $167.44 million in cash and short-term investments compared to $47.65 million in total debt. The company posted a net income of -$42.35 million in the quarter, while revenues of -$49.26 million were grew 42.03%. The analyst consensus anticipated IVERIC bio Inc.’s latest quarter earnings to come in at -$0.31 per share, but it turned out to be -$0.41, a -32.30% surprise. Shareholders own equity worth $120.72 million.
From a technical analysis perspective, let’s take a brief look at IVERIC bio Inc. (ISEE) price momentum. RSI 9-day as of the close on 28 December was 42.86%, suggesting the stock is Neutral, with historical volatility in this time frame at 53.11%.
As of today, ISEE’s price is $22.04 -6.82% or -$1.54 from its 5-day moving average. ISEE is currently trading -7.76% lower than its 20-day SMA and +64.17% higher than its 100-day SMA. However, the stock’s current price level is -4.02% below the SMA50 and +50.32% above the SMA200.
The stochastic %K and %D were 40.57% and 54.86%, respectively, and the average true range (ATR) was 1.05. With the 14-day stochastic at 29.97% and the average true range at 1.11, the RSI (14) stands at 46.57%. The stock has reached -0.68 on the 9-day MACD Oscillator while the 14-day reading was at -0.48.
Jefferies downgraded IVERIC bio Inc. (NASDAQ: ISEE) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for IVERIC bio Inc. (ISEE) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ISEE, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is ISEE’s price target for the next 12 months?
Analysts predict a range of price targets between $17.00 and $35.00, with a median target of $30.00. Taking a look at these predictions, the average price target given by analysts for IVERIC bio Inc. (ISEE) stock is $29.17.